Key result
DEFINITY labeling revisions reflect growing literature support for its excellent risk-benefit profile.
Answers are grounded in this paper and cite their sources.
The regulatory history of DEFINITY highlights how post-market data can shape product labeling to reflect a favorable risk-benefit profile in echocardiography.
DEFINITY® (Perflutren Lipid Microsphere Injectable Suspension, Lantheus Medical Imaging, North Billerica, MA) was approved by the US Food and Drug Administration in 2001 for “opacification of the left ventricular border in patients with technically difficult echocardiograms”. Since then, product labeling has been substantially revised on three occasions, initially due to safety concerns, and more recently to reflect a large body of literature which supports the excellent risk–benefit profile of this agent. This article describes in detail the substantive modifications of the product labeling for DEFINITY since 2001, and the associated supportive scientific data and public regulatory meetings.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2012) conducted a review in Technically difficult echocardiograms. DEFINITY (Perflutren Lipid Microsphere Injectable Suspension) was evaluated. Product labeling for DEFINITY has been substantially revised three times since 2001, initially for safety concerns and later reflecting literature supporting its excellent risk-benefit profile.
Synapse has enriched 10 related papers. Consider them for comparative context: